BP’s Core Laboratories CLB Stock Holding History

BP’s Portfolio CLB Stock Details CLB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-6,000	Closed	-$757K	–	489
2018 Q2	$757K	Buy	+6,000	New	+$730K	0.02%	473

Other funds holding CLB

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Royal London Asset Management United Kingdom $54.3B AUM 39.21% 1-Year Est. Return

EIP

Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

BP's CLB Position: Q3 2018 in Review

BP sold out of Core Laboratories (CLB) in Q3 2018, closing a stake of 6,000 shares — an estimated $757K sold.

BP first reported a position in CLB in Q2 2018 and held it in 1 quarter. The position peaked at $757K in Q2 2018. 359 funds tracked by Wall St. Rank hold CLB as of Q3 2018.

BP reported no remaining Core Laboratories position as of Q3 2018 after selling out during the quarter.
BP sold 6,000 Core Laboratories shares in Q3 2018, an estimated $757K.
BP first reported a position in Core Laboratories in Q2 2018 and held it in 1 quarter.
BP's Core Laboratories position peaked at $757K in Q2 2018.
359 funds tracked by Wall St. Rank held Core Laboratories as of Q3 2018.

Based on BP's 13F filing for Q3 2018, filed 2 Nov 2018.